GLP-1 cost: prices, discounts, and insurance coverage

Brand-name GLP-1 medications carry high list prices when you pay cash without insurance, often in the range of roughly $1,000 to $1,350 per month. For many people considering treatment for obesity or type 2 diabetes, that number can end the conversation before it starts. A structured set of manufacturer self-pay programs, savings cards, and a new federal access pathway has changed that picture, with some cash-pay routes now starting near $149 per month for the lowest doses.

FindDrugs.org is an independent research organization. Its content is based on primary sources, including manufacturer pricing pages, FDA records, and official federal agency announcements. It does not accept compensation for product promotion and maintains strict neutrality across all medication categories. Prices change frequently and vary by dose, pharmacy, and location, so treat the figures below as reference points to verify at the point of purchase. All medical decisions should be made in consultation with a qualified clinician.

The sections below break down cash-pay pricing for the major semaglutide, tirzepatide, and orforglipron products, then cover manufacturer-direct programs, discount platforms, compounded alternatives, and the temporary Medicare GLP-1 Bridge that began in mid-2026. If you are comparing providers rather than just prices, see our roundup of the best GLP-1 providers.

Key Takeaways

• Brand-name GLP-1 medications generally list around $1,000 to $1,350 per month without insurance, but manufacturer self-pay programs and savings cards can lower the effective cost substantially.
• Manufacturer savings (copay) cards from Novo Nordisk and Eli Lilly can reduce cost to as little as $25 per month, but only for patients with active commercial insurance coverage.
• Foundayo (orforglipron), an oral GLP-1 approved in 2026, is sold through LillyDirect on a dose-tiered self-pay schedule.
• Compounded GLP-1 alternatives are typically reported in the $100 to $300 range through telehealth providers, but they are not FDA-approved, and a 2026 FDA proposal could restrict their availability.
• Manufacturer-direct programs (LillyDirect for Zepbound, NovoCare for Ozempic and Wegovy) offer structured self-pay pricing without traditional insurance.
• Starting July 1, 2026, eligible Medicare Part D members can access Foundayo, Wegovy, or Zepbound (KwikPen) for a $50 monthly copay through the CMS GLP-1 Bridge, which runs through December 31, 2027.

Average costs of GLP-1 medications without insurance

GLP-1 medications range from hundreds to over a thousand dollars each month at cash prices. Understanding the list prices for the major semaglutide and tirzepatide products is the first step before comparing cost-reduction options.

Wegovy and Ozempic

Wegovy and Ozempic are the most widely recognized injectable GLP-1 medications, both manufactured by Novo Nordisk. Wegovy is indicated for weight management and Ozempic for type 2 diabetes. Ozempic is available only as a once-weekly injection; the once-daily oral semaglutide tablet sold for diabetes is a separate product, Rybelsus. Novo Nordisk also offers an oral tablet form of Wegovy for weight management.

NovoCare Pharmacy, Novo Nordisk's direct delivery service, publishes these self-pay rates directly. The introductory Wegovy injection price of $199 applies only to the first two fills before the standard $349 self-pay rate applies. Manufacturer savings cards can lower the monthly cost to as little as $25, but eligibility is generally restricted to patients with active commercial insurance; uninsured patients cannot use them.

The gap between the published list price and the self-pay or savings-card price is the reason it is worth comparing purchasing channels, including retail pharmacies and manufacturer-direct programs, before committing to a single source.

Zepbound and Mounjaro

Zepbound and Mounjaro are both tirzepatide products from Eli Lilly. Zepbound is indicated for weight management in adults and Mounjaro for type 2 diabetes in adults. Both carry high list prices, with structured self-pay pathways for patients paying cash.

Eli Lilly's savings cards can reduce the cost of Zepbound or Mounjaro to as little as $25 per one-, two-, or three-month fill for patients who meet the commercial-insurance eligibility rules. Zepbound is also available through LillyDirect, Eli Lilly's direct-to-consumer platform, with single-dose vial self-pay pricing described in the manufacturer-direct section below.

A significant development for Medicare-eligible patients took effect in 2026. CMS launched a temporary Medicare GLP-1 Bridge on July 1, 2026. Eligible Part D members can obtain Foundayo (tablet), Wegovy (injection or tablet), or Zepbound (KwikPen only) for a $50 copay per monthly supply through December 31, 2027. Single-dose Zepbound vials and pens are not covered by the program.

According to CMS, beneficiaries must be 18 or older, be using the medication for weight reduction alongside a lifestyle program, and meet one of the following at the time GLP-1 therapy begins:

• BMI of 35 or higher, with no additional condition required
• BMI of 30 or higher with diastolic heart failure (HFpEF), uncontrolled hypertension, or chronic kidney disease stage 3a or above
• BMI of 27 or higher with pre-diabetes, a prior heart attack, a prior stroke, or symptomatic peripheral artery disease

CMS also notes exclusions: beneficiaries are not eligible through the Bridge if their Part D plan already covers a GLP-1 for them, or if they qualify for coverage under an existing Part D indication such as type 2 diabetes, moderate-to-severe sleep apnea, or MASH. Eligibility rules and covered products can change, so verify current details with CMS or your plan.

Oral GLP-1 options

Oral GLP-1 medications offer an alternative to injections. Pricing varies significantly by product, dose, and purchasing channel.

Foundayo (orforglipron) received FDA approval in April 2026 and launched on April 9, 2026, as the first oral GLP-1 pill for weight loss that can be taken at any time of day without food or water restrictions. Its list price is $649 per month, and LillyDirect offers dose-tiered self-pay pricing.

The tiered structure matters for realistic budgeting. Many patients advance to therapeutic doses within the first few months, which places ongoing monthly self-pay costs in the $299 to $349 range rather than the $149 entry level. The $25 savings card applies only to patients who meet the commercial-insurance eligibility requirements. Because discount-platform prices for oral GLP-1 products fluctuate by pharmacy and location, confirm current dose-specific pricing directly with your pharmacy before filling.

Cheapest cash-pay options for GLP-1 medications

Several structured programs offer meaningful savings on GLP-1 receptor agonists without requiring health insurance. The main approaches are manufacturer-direct channels, pharmacy discount platforms, and compounded alternatives through telehealth providers.

Manufacturer-direct programs (LillyDirect, NovoCare)

Manufacturer-direct programs connect patients to the pharmaceutical company without a retail intermediary, often at structured self-pay prices below standard pharmacy rates.

LillyDirect (Zepbound): Eli Lilly's single-dose vial self-pay pricing through LillyDirect is tiered by dose:

• 2.5 mg vial: $299 per month
• 5 mg vial: $399 per month
• 7.5 mg to 15 mg vials: $449 per month

One detail within the program is a 45-day refill window. If that window is missed, pricing on higher doses reverts to the regular self-pay rates, currently around $499 to $699 per month depending on strength. Setting consistent refill reminders helps avoid the higher rate.

NovoCare Pharmacy (Ozempic and Wegovy): NovoCare delivers Ozempic at $349 per month for the 0.25, 0.5, or 1 mg doses and $499 per month for the 2 mg dose. Wegovy self-pay through NovoCare is $349 per month for standard pen strengths, with an introductory rate of $199 per month for the first two fills.

Key program conditions to review before enrolling:

• Eligibility criteria apply to all manufacturer programs
• A healthcare provider must confirm the medication is appropriate
• Some presentations or doses may be excluded from a given self-pay rate
• Introductory pricing can differ from the ongoing monthly rate

Prescription discount programs

Prescription discount platforms aggregate pricing across pharmacies and surface the lowest available cash rate at the point of dispensing. Because those rates change frequently and vary by pharmacy and location, they are best treated as a comparison tool rather than a fixed price. Comparing more than one platform, along with the manufacturer self-pay programs above, before filling can help identify the lowest available rate for a specific medication and pharmacy.

Older GLP-1 agents such as Trulicity, Victoza, and Saxenda generally carry higher cash prices than the newer products and do not benefit from the introductory self-pay pricing seen on recent launches. For those medications, the manufacturer's published list price and any patient-assistance program are the most reliable reference points.

Compounded alternatives

Compounded GLP-1 medications are prepared by compounding pharmacies and have been offered through some telehealth providers for cash rates below brand-name list prices. These providers typically bundle a consultation fee and shipping into a single monthly charge, and access does not require traditional insurance approval.

Several limitations are important to understand:

• Compounded drugs are not FDA-approved and have not undergone the standardized safety and efficacy review that approved products have
• Most insurance plans and manufacturer savings cards do not cover compounded versions
• Patients typically bear the full cost, with no discount-program overlap
• These products are generally used off-label and may not carry the same evidence base as FDA-approved counterparts

There is also a regulatory development that directly affects this pricing tier. On April 30, 2026, the FDA proposed to exclude semaglutide, tirzepatide, and liraglutide from the 503B bulk-compounding list, stating it did not identify a clinical need for outsourcing facilities to compound these drugs from bulk substances. This followed the resolution of their drug shortages, with tirzepatide's shortage determined resolved in December 2024 and semaglutide's in February 2025. The proposal was published in the Federal Register on May 1, 2026, and the FDA has not announced a final-decision timeline; the public comment period was extended into mid-2026. If finalized, the rule would curtail large-scale compounding of these drugs, which could affect the availability of the lower-cost compounded tier.

Cost comparison: brand-name vs. compounded GLP-1 medications

The price difference between brand-name and compounded GLP-1 receptor agonists is large, but cost is not the only variable. Regulatory status, access to savings programs, and supply stability all factor into the comparison.

Brand-name GLP-1 receptor agonists have undergone FDA review for purity, potency, safety, and efficacy, and manufacturer savings and patient-assistance programs are accessible through official channels. Cash-pay self-pay rates begin as low as $149 per month for the lowest oral dose, with ongoing rates that climb depending on product and dose. Compounded semaglutide or tirzepatide is cheaper at the point of sale but lacks FDA review, cannot use manufacturer savings cards, and now carries the supply uncertainty introduced by the proposed FDA restriction on 503B bulk compounding.

Tips to reduce GLP-1 costs without insurance

Several strategies can help reduce out-of-pocket cost, depending on eligibility and individual circumstances.

Explore manufacturer savings cards

Manufacturer savings cards from Novo Nordisk and Eli Lilly can reduce the monthly cost of products such as Ozempic, Wegovy, Zepbound, and Mounjaro to as little as $25 for a one-, two-, or three-month supply. The key restriction is that patients must have active commercial insurance to use these cards; uninsured patients cannot. Separate patient-assistance programs from both manufacturers may provide a pathway for patients with no coverage. Each manufacturer sets its own eligibility rules by product, so confirm eligibility directly with the relevant program. These cards do not apply to compounded alternatives.

Consider self-pay and telehealth options

Manufacturer self-pay programs (LillyDirect and NovoCare) and some telehealth platforms offer structured cash pricing without insurance. Telehealth providers that supply compounded GLP-1 products are not eligible for manufacturer savings programs or copay cards, so the quoted price is the price paid. Anyone weighing a compounded option should also factor in the pending FDA proposal to restrict 503B bulk compounding, which could affect pricing and availability. Verifying a provider's licensing and confirming that qualified clinicians oversee prescriptions are essential steps before purchasing from any telehealth platform.

Research local pharmacy discounts

Local pharmacy pricing can vary from national averages. Calling ahead to ask about in-store coupons, loyalty programs, and price matching for Wegovy, Ozempic, Zepbound, and Mounjaro is a practical starting point. Prescription discount cards let patients compare prices across pharmacies, and talking directly with a pharmacist about dose-specific savings can surface additional options.

Comparing your lowest-cost options

The best choice depends on budget, medical needs, and eligibility for available programs. The following represent the main cost tiers for uninsured patients as of mid-2026:

• Oral GLP-1s (lowest entry cost): Foundayo starts at $149 per month for the lowest dose, with ongoing therapeutic doses typically $299 to $349 monthly.
• Manufacturer-direct programs: LillyDirect and NovoCare offer structured self-pay access, subject to program terms such as the 45-day refill window for LillyDirect.
• Medicare GLP-1 Bridge: Eligible Part D members access certain GLP-1 medications for $50 per month through December 31, 2027.
• Discount platforms: Prescription discount cards can surface lower cash rates that vary by pharmacy and location.
• Compounded alternatives: offered at cash rates below brand-name list prices, though these are not FDA-approved and face potential supply restrictions.

Comparing several programs before committing tends to serve uninsured patients best. To weigh specific telehealth and provider options rather than prices alone, see our roundup of the best GLP-1 providers. A healthcare provider should guide product selection based on individual health goals and medical factors, not cost alone.

Conclusion

Finding an affordable GLP-1 medication without insurance means comparing several cost-reduction pathways. List prices for brand-name products generally run about $1,000 to $1,350 per month, but manufacturer self-pay programs, savings cards, and the Medicare GLP-1 Bridge can lower the effective cost considerably for those who qualify. Savings cards from Eli Lilly and Novo Nordisk can reduce cost to as little as $25 per month for patients with commercial insurance, and eligible Medicare Part D members can access covered GLP-1s for $50 per month through the Bridge program. Because prices change and eligibility rules vary, comparing current options across programs, and confirming details with the manufacturer, pharmacy, or CMS, remains the most reliable approach. A qualified clinician should guide the final medication choice based on health needs, not cost alone.

FAQs

1. What is the lowest-cost GLP-1 without insurance?

Among FDA-approved products, the lowest cash entry point is an oral GLP-1 self-pay tier: Foundayo (orforglipron) starts at $149 per month for the 0.8 mg dose through LillyDirect, though most patients advance to higher doses priced at $299 to $349. Compounded semaglutide or tirzepatide is often reported lower, in the $100 to $300 range through telehealth providers, but it is not FDA-approved and may face supply restrictions under a pending FDA proposal.

2. How much does a GLP-1 cost without insurance?

Brand-name GLP-1 medications generally list around $1,000 to $1,350 per month without insurance. Manufacturer self-pay programs and savings cards can lower the effective cost; savings cards can bring it to as little as $25 per month, but only for patients with commercial insurance.

3. Can Medicare help cover GLP-1 costs?

Starting July 1, 2026, the temporary CMS Medicare GLP-1 Bridge lets eligible Part D members obtain Foundayo, Wegovy, or Zepbound (KwikPen) for a $50 monthly copay through December 31, 2027, subject to BMI and clinical eligibility criteria. Coverage under a plan's standard Part D benefit can also apply for FDA-approved indications, so members should review their formulary.

4. Do manufacturer savings cards work if I am uninsured?

No. The $25 savings cards from Novo Nordisk and Eli Lilly generally require active commercial insurance. Uninsured patients cannot use them, but may be able to use manufacturer self-pay programs (LillyDirect, NovoCare) or separate patient-assistance programs instead.